P/N 53063-50, Manual Revision: B
Appendices
APP-5
Malignancy
A. Primary at Operative Site
Cell salvage is widely used
in surgical excision of
malignant tumors. The
available data would tend
to indicate that the
procedure is safe and does
not increase the incidence
of metastatic disease.
However, since a control
trial has not been
performed (and it is
questionable whether it will
ever be performed), the
decision to use cell salvage
in malignancies must be left
to the discretion of the
surgeon.
Avoid cell salvaging at tumor site.
Medical risks and benefits should be
discussed between the surgeon and
the medical director of the surgical
services program.
Consider the use of a
leukoreduction filter.
B. Metastatic at Operative Site
Potential for further spread
of disease.
Disease already systemic. Use at
discretion of surgeon.
C. Pheochromocytoma
Potential for marked
hypertension due to high
concentrations of
catecholamines.
Avoid aspirating at the tumor site.
Resumption is an option after
copious irrigation with 0.9% sodium
chloride solution to an alternate
suction source.
D. Ascites
Tumor cells may be present.
Avoid aspirating into the system if
the surgical procedure is for ovarian
malignancy.
Hematologic Disorders
A. Sickle Cell Trait
Wash procedure produces
potential sickling of
salvaged cells.
Alert staff of potential for red cell
sickling.
B. Confirmed Sickle Cell Anemia
Wash procedure produces
potential sickling of
salvaged cells.
Medical risks and benefits should be
discussed between the surgeon and
the medical director of the surgical
services program.
Complications of and contraindications to perioperative blood recovery
1
(Per 1997 AABB Guidelines for blood recovery and reinfusion in surgery and trauma pg 19-22)
Substance
Effects
Recommended Action
